

The ps transient absorption spectra of the ethyletioporphyrin (EEP)-toluquinone (TQ) system were measured with a micro-computer-controlled Nd<sup>3+</sup>:YAG laser photolysis system.<sup>5</sup> In acetone (Figure 1), where EEP fluorescence is almost completely quenched by TQ, the transient spectra are very similar to the S<sub>n</sub> ← S<sub>1</sub> spectra of EEP itself. We obtained the decay time of this transient absorbance as  $\tau_{\text{obsd}} \approx 70$  ps, which was in approximate agreement with the value ( $\sim 80$  ps) estimated from the relation  $\tau_{\text{calcd}} S_1 = \tau_0 / (1 + k_q \tau_0 [\text{TQ}])$  with  $\tau_0$  and  $k_q$  values determined in the present work. These results indicate that the excited EEP in acetone is quenched by encounter collision with TQ but the produced ion pair is immediately deactivated without producing separated ion radicals. Moreover, an examination of the ground-state absorption spectra and the relationship between fluorescence yield and [TQ] reveals that about 66% of EEP forms a ground-state loose complex with TQ in acetone.<sup>6</sup> In the light of the above results of ps transient absorption studies, this fact leads to the conclusion that the loose complex undergoes ultrafast deactivation via a solvated ET state or ion-pair state immediately after excitation.

Contrary to the above results, the ps transient absorption spectra in benzene (Figure 2) are quite different from the S<sub>n</sub> ← S<sub>1</sub> spectra of EEP. The absorption band shows a maximum around 650–700 nm, and its intensity drops strongly in the longer wavelength side (in contrast to the EEP S<sub>n</sub> ← S<sub>1</sub> spectra, which show a flat band in this region) and is similar to that of porphyrin cation.<sup>7</sup> Moreover, it has been confirmed that about 90% of EEP forms a loose complex in benzene solution.<sup>6</sup> Since the TQ anion does not show an absorption band in this wavelength region, the transient absorption spectra in Figure 2 can be assigned to the exciplex (EEP<sup>+</sup>·TQ<sup>-</sup>) formed by the excitation of the loose complex. We obtained the decay time of this exciplex as  $\tau_{\text{obsd}} \approx 40$  ps. This  $\tau_{\text{obsd}}$  is much shorter than the  $\tau_{\text{calcd}} S_1$  ( $\sim 130$  ps) obtained by assuming encounter collisional quenching.

The above results provide a direct connection between the porphyrin-quinone system and the typical exciplexes. Although it is rather short-lived, the porphyrin-quinone exciplex can be observed in nonpolar solvents, while the photoinduced ET state undergoes ultrafast deactivation to the ground state in polar solvents. Solvation in the ET state lowers its energy but lifts up the energy of the neutral ground state compared to that relaxed with respect to solvation,<sup>3c</sup> which results in a very small energy gap between two states leading to the ultrafast deactivation in the porphyrin-quinone system.<sup>6</sup> We have confirmed the same result also in the excited EDA complex of pyromellitic dianhydride-pyrene.<sup>8</sup> However, the energy gap in the case of typical exciplexes such as pyrene-DMA or -DCNB is not so small, according to our estimate of the solvation energy.<sup>6,8</sup>

We have examined also the exciplex systems of the cyclophane type face to face porphyrin dimer (FTFP) (etioporphyrins combined by two (CH<sub>2</sub>)<sub>2</sub>-CO-NR-(CH<sub>2</sub>)<sub>2</sub> chains) and TQ. The ps transient absorption spectra of the FTFP-TQ system in benzene can be assigned to the exciplex (FTFP<sup>+</sup>·TQ<sup>-</sup>) since they are similar to that of the FTFP cation,<sup>7c</sup> the decay time of which was shorter than 25 ps according to our measurement. The shorter  $\tau_{\text{obsd}}$  compared to the EEP-TQ system can be ascribed to the faster nonradiative deactivation owing to the smaller energy gap between the ET and ground states for the FTFP-TQ system, since the oxidation potential of FTFP is a little lower than that of the EEP, according to our measurement. The lower oxidation potential indicates some delocalization interaction between two porphyrin rings. Therefore, the delocalization of positive charge over two porphyrin rings has little effect for lengthening the ET state

lifetime. In acetone, no ET state was observed due to the ultrafast deactivation.

The above results clearly demonstrate the crucial role of a polar environment that causes ultrafast deactivation of porphyrin-quinone ET state. This finding is very important for designing biomimetic artificial photosynthetic systems.

### **trans-6-Amino-5-[(1-carboxyethenyl)oxy]-1,3-cyclohexadiene-1-carboxylic Acid: An Intermediate in the Biosynthesis of Anthranilate from Chorismate**

Peter P. Policastro, Karin G. Au, Christopher T. Walsh,\* and Glenn A. Berchtold\*

Department of Chemistry  
Massachusetts Institute of Technology  
Cambridge, Massachusetts 02139

Received October 18, 1983

Revised Manuscript Received February 14, 1984

Microorganisms utilize chorismate (**1**) for the biosynthesis of tryptophan.<sup>1</sup> The initial enzymatic reaction, the conversion of **1** to anthranilate (**2**), is catalyzed by anthranilate synthase, and the amide nitrogen of glutamine serves as the nitrogen source.<sup>2,3</sup> The enzyme from *Serratia marcescens* and other enteric bacteria has two subunits. One subunit (AS I) catalyzes the conversion of **1** and NH<sub>3</sub> to **2** and pyruvate. The other subunit (AS II) serves as the glutamine amidotransferase. It has been established that the nitrogen atom becomes attached at C-2 of **1**,<sup>4</sup> and the C-2 hydrogen atom of **1** is not incorporated into the pyruvate formed in the reaction.<sup>5,6</sup>

Amino acid **3** (Scheme I) has been postulated as the intermediate in the biosynthesis of **2** from **1**,<sup>4,7</sup> but attempts to isolate an intermediate have not been successful.<sup>8</sup> It has been suggested that the stereochemistry of **3** ought to be cis rather than trans.<sup>1a</sup> The isolation of *trans*-2,3-dihydro-3-hydroxyanthranilic acid from a strain of *Streptomyces aureofaciens*,<sup>9</sup> however, suggests that **3** is the metabolic intermediate. Described below are our synthesis of ( $\pm$ )-**3** and the enzyme-catalyzed transformation of **3** to **2** with *S. marcescens* AS I from a plasmid-containing *E. coli* strain.<sup>10</sup>

Carbamate **5** (Scheme II), prepared in 10% yield from the Diels-Alder reaction of methyl propiolate and *tert*-butyl *trans*-1,3-butadiene-1-carbamate,<sup>11</sup> was epoxidized (*m*-chloroperoxybenzoic acid, CH<sub>2</sub>Cl<sub>2</sub>), and the epoxide was isomerized to **6**<sup>12</sup> with 1,3-diazabicyclo[5.4.0]undec-7-ene in THF (40% from **5**). Re-

(1) (a) Weiss, U.; Edwards, J. M. "The Biosynthesis of Aromatic Compounds"; Wiley: New York, 1980; pp 238-246. (b) Haslam, E. "The Shikimate Pathway"; Wiley: New York, 1974; pp 23-42. (c) Ganem, B. *Tetrahedron* **1978**, *34*, 3353-3383.

(2) Srinivasan, P. R.; Rivera, A. *Biochemistry* **1963**, *2*, 1059-1062.

(3) Edwards, J. M.; Gibson, F.; Jackman, L. M.; Shannon, J. S. *Biochim. Biophys. Acta* **1964**, *93*, 78-84.

(4) Srinivasan, P. R. *Biochemistry* **1965**, *4*, 2860-2865.

(5) (a) Onderka, D. K.; Floss, H. G. *Fed. Proc.* **1969**, *28*, 668. (b) Floss, H. G.; Onderka, D. K.; Zalkin, H. *Biochim. Biophys. Acta* **1970**, *206*, 449-456.

(6) Tamir, H.; Srinivasan, P. R. *Proc. Natl. Acad. Sci. U.S.A.* **1970**, *66*, 547-551.

(7) Levin, J. G.; Sprinson, D. B. *J. Biol. Chem.* **1963**, *239*, 1142-1150.

(8) (a) Lingens, F. *Angew. Chem., Int. Ed. Engl.* **1968**, *7*, 350-360. (b) Lingens, F.; Sprössler, B.; Goebel, W. *Biochim. Biophys. Acta* **1966**, *121*, 164-166. (c) Lingens, F.; Goebel, N. *Hoppe-Seyler's Z. Physiol. Chem.* **1965**, *342*, 1-12. (d) Lingens, F.; Lück, W.; Goebel, W. *Z. Naturforsch. B* **1963**, *18B*, 851.

(9) (a) McCormick, J. R. D.; Reichenthal, J.; Uirsch, U.; Sjolander, N. O. *J. Am. Chem. Soc.* **1962**, *84*, 3711-3714. (b) Hashimoto, T.; Kondo, S.; Naganawa, H.; Takita, T.; Maeda, K.; Umezawa, H. *J. Antibiot.* **1974**, *27*, 86-87.

(10) We thank Professor H. Zalkin for providing AS I from *S. marcescens* (specific activity: 0.522 U/mg).

(11) Jessup, P. J.; Petty, C. B.; Roos, J.; Overman, L. E. *Org. Synth.* **1979**, *59*, 1-9.

(12) Satisfactory spectral data have been obtained for all new substances described. Satisfactory analytical data (high-resolution mass spectrum) have been obtained for **6**, **7**, **9**, and **3-TFA**. High-resolution mass spectra were provided by the facility supported by National Institutes of Health Grant RR00317 (principal investigator Professor K. Biemann) from the Biotechnology Resources Branch, Division of Research Resources.


(5) (a) Miyasaka, H.; Masuhara, H.; Mataga, N. *Laser Chem.* **1983**, *1*, 357. (b) Ikeda, N.; Miyasaka, H.; Okada, T.; Mataga, N. *J. Am. Chem. Soc.* **1983**, *105*, 5206. (c) Martin, M. M.; Ikeda, N.; Okada, T.; Mataga, N. *J. Phys. Chem.* **1982**, *86*, 4148.

(6) Mataga, N.; Karen, A.; Okada, T., manuscript in preparation.


(7) (a) Fuhrhop, J. H.; Mauzerall, D. J. *J. Am. Chem. Soc.* **1969**, *91*, 4174. (b) Bonnett, R.; Lambert, C.; Land, E. J.; Scourides, P. A.; Sinclair, R. S.; Truscott, T. G. *Photochem. Photobiol.* **1983**, *38*, 1. (c) Karen, A.; Mataga, N., unpublished results.

(8) Shioyama, H.; Mataga, N., manuscript in preparation.

Scheme I



Scheme II



action of 6 with dimethyl diazomalonate and 1 mol %  $\text{Rh}_2(\text{OAc})_4$  in benzene at 65 °C gave 7 (56%).<sup>13</sup> Reaction of 7 with Eschenmoser's salt [ $\text{CH}_2=\text{N}(\text{CH}_3)_2^+\text{I}^-$ ,  $(\text{C}_2\text{H}_5)_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ] and quaternization of the Mannich base ( $\text{CH}_3\text{I}$ ,  $\text{CH}_2\text{Cl}_2$ ) provided 8 (100%). Base-induced fragmentation (1.5 equiv of  $\text{NaOH}$ ,  $\text{THF}/\text{H}_2\text{O}$ , 0 °C, 45 min) gave 9<sup>14</sup> (46%). Saponification of 9 (2.2 equiv of  $\text{NaOH}$ ,  $\text{THF}/\text{H}_2\text{O}$ , 4 °C, 40 h) followed by acidification with Amberlite IR-120 resin afforded 10 (94%). Treatment of 10 with dry, freshly distilled  $\text{CF}_3\text{CO}_2\text{H}$  (TFA) at 0 °C for 15 min followed by workup gave salt 3-TFA (43%).<sup>15,16</sup>

To test compound 3 as a potential intermediate in the enzymic biosynthesis of anthranilate from chorismate and ammonia, samples of the trifluoroacetate salt, 3-TFA, were incubated with pure *S. marcescens* AS I enzyme.<sup>17</sup> For comparison chorismate,<sup>18</sup> with or without ammonia, was used as control substrate. Compound 3 was an excellent substrate, undergoing enzymic conversion

(13) Procedure of Ganem, B.; Ikota, N.; Muralidharan, V. B.; Wade, W. S.; Young, S. D.; Yukimoto, Y. *J. Am. Chem. Soc.* **1982**, *104*, 6787-6788.

(14) Trans stereochemistry for the substituents at  $\text{C}_5$  and  $\text{C}_6$  of 9 was established from the  $^1\text{H}$  NMR spectrum of the products from reaction of 9 with 4-phenyl-1,2,4-triazoline-3,5-dione. Two Diels-Alder adducts were formed. For one adduct  $J = 2.9$  Hz for the two H's derived from  $\text{H}_5$  and  $\text{H}_6$  of 9. The corresponding  $J$  for the other adduct was 1.8 Hz.

(15) 3-TFA: mp 93-95 °C; IR (KBr) 3600-3250, 1685, 1630  $\text{cm}^{-1}$ ; UV ( $\text{H}_2\text{O}$ ), 280 nm ( $\epsilon$  5900);  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ )  $\delta$  7.37 (1 H, d,  $J = 5$  Hz), 6.47 (2 H, m), 5.63 (1 H, d,  $J = 3$  Hz), 5.07 (1 H, d,  $J = 3$  Hz), 4.53 (1 H, d,  $J = 6$  Hz), the remaining absorption is obscured by the DOH peak.

(16) Salt 3-TFA is a white, nonhygroscopic powder. The neutral amino acid (hygroscopic) can be obtained by eluting a cold aqueous solution of 3-TFA through a column of ion-retardation resin AG11A8 (Bio-Rad Corp). The material is most conveniently handled in salt form.

(17) Assay conditions were adapted from Zalkin and Kling (Zalkin, H.; Kling, D. *Biochemistry* **1968**, *7*, 3566-3573) and were performed at 26 °C with a Perkin-Elmer LS-3 Fluorimeter. Buffers were adjusted to be pH 8.6 with or without  $\text{NH}_4^+$ .

(18) Chorismate was isolated from culture growth of *K. pneumoniae* 62-1 (formerly *A. aerogenes* 62-1) according to: Gibson, F. *Methods Enzymol.* **1970**, *17A*, 362-364. We thank Professor F. Gibson for a generous gift of *K. pneumoniae* 62-1.

to anthranilate<sup>19</sup> in the absence of  $\text{NH}_4^+$  with a  $K_m$  of 0.2 mM and  $V_{\text{max}}$  of 300 (nmol/min)/mg enzyme compared to a  $K_m$  of 0.11 mM and  $V_{\text{max}}$  of 500 (nmol/min)/mg for the natural substrate chorismate<sup>17,20</sup> in the presence of ammonia. In the absence of  $\text{NH}_4^+$  ions, chorismate gave no anthranilate. Addition of 50 mM  $\text{NH}_4^+$  to enzymic incubations of 3-TFA did increase  $V_{\text{max}}$  values ca. 2-fold such that under these conditions 3-TFA was processed to anthranilate at higher  $V_{\text{max}}$  than chorismate so 3-TFA is both a kinetically and chemically competent candidate for a reaction intermediate.

It was anticipated that anthranilate synthase would act stereospecifically on only one of the enantiomers of ( $\pm$ )-3-TFA, presumably the 5*S*,6*S* isomer. In incubations containing 0.2-3.2 mM 3-TFA<sup>15</sup> with varying enzyme levels, we routinely observed 24-27% conversion in the absence of  $\text{NH}_4^+$  and 35% in the presence of  $\text{NH}_4^+$  by fluorescence assay.<sup>17</sup> In parallel incubations where coproduct pyruvate (4) was monitored by coupled in situ reduction by *L*-lactate dehydrogenase and NADH, 34-35% conversions were detected, with or without added  $\text{NH}_4^+$ . This is substantial conversion but less than 50% for reasons as yet unclear.<sup>21</sup>

In sum, compound 3 is processed enzymically to anthranilate by the *S. marcescens* synthase at rates that support its role as reaction intermediate and thereby substantiate the mechanism of Scheme I for this enzyme, with trans geometry in the amino enol pyruvyl intermediate.

**Acknowledgment.** We are grateful to Professor H. Zalkin for a generous gift of AS I from *S. marcescens*, to the National Institutes of Health, Grants GM 20011 and GM 31958, for financial support, and to the National Science Foundation for a predoctoral fellowship to K.G.A.

**Supplementary Material Available:** Physical data for 6, 7, 9, and 3-TFA (1 page). Ordering information is given on any current masthead page.

(19) Monitored as in ref 17 and also by TLC on silica plates, developed in 80:18:2 ether:hexane:acetic acid and 93:5:2  $\text{CHCl}_3$ : $\text{CH}_3\text{OH}$ : $\text{CH}_2\text{COOH}$ .

(20) Tso, J. Y.; Zalkin, H. *J. Biol. Chem.* **1981**, *256*, 9901-9908.

(21) The extent of conversion did not reflect any inhibition by  $\text{K}^+\text{TFA}^-$ , nor was it increased by additional amounts of enzyme. It is conceivable but not obviously due to enzyme inactivation or to nonenzymic breakdown of 3-TFA during incubations on the basis of the experimental results reported herein.

## <sup>57</sup>Fe NMR: Relaxation Mechanisms and Chemical Shifts

Lars Baltzer,\*<sup>1a,b</sup> Edwin D. Becker,<sup>1a</sup> B. A. Averill,<sup>1c,d</sup>  
J. M. Hutchinson,<sup>1c,e</sup> and Otto A. Gansow\*<sup>1a,e,f</sup>

National Institutes of Health  
Bethesda, Maryland 20205  
Department of Chemistry, Michigan State University  
East Lansing, Michigan 48824  
Department of Chemistry, Alma College  
Alma, Michigan 48801

Received November 15, 1983

Despite the importance of iron in biological, organometallic, and coordination chemistry, only limited studies of <sup>57</sup>Fe NMR have been reported.<sup>2-7</sup> <sup>57</sup>Fe, the only isotope of iron suitable for

(1) (a) Laboratory of Chemical Physics, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, NIH. (b) Fellow of the Swedish Natural Science Research Council, 1981-1983. Present address: Department of Organic Chemistry, University of Göteborg and Chalmers University of Technology, S-41296, Göteborg, Sweden. (c) Michigan State University. (d) Fellow of the Alfred P. Sloan Foundation, 1981-1984. Present address: University of Virginia, Charlottesville, VA. (e) Alma College. (f) National Cancer Institute, Building 10, Room B3-B69, National Institutes of Health, Bethesda, MD 20205.

(2) Schwenk, A. *Phys. Lett. A* **1970**, *31A*, 513.

(3) Sahn, W.; Schwenk, A. *Z. Naturforsch.*, **1974**, *29A*, 1793.